Ainos Regains Nasdaq Compliance, Sets 90-Day Roadmap to Scale AI Nose Platform in 2026

Rhea-AI Summary

Ainos (NASDAQ:AIMD) has regained Nasdaq compliance and unveiled its 90-day roadmap for scaling its AI Nose platform. The company reported significant achievements, including a 412% year-over-year revenue increase in Q1 2025 and strategic partnerships with major industry players like ASE Technology Holding for deploying up to 15,000 AI Nose units.

The company's proprietary smell language model (SLM) has achieved 90% accuracy in classifying everyday scents, while its senior care program improved to 85% accuracy. Key partnerships with Kenmec and Solomon aim to integrate AI-powered scent intelligence into smart factory systems. The company also completed the first-ever integration of AI Nose with a humanoid robot through ugo Inc.

Ainos's 90-day plan focuses on deploying 1,400 AI Nose units with ASEH, expanding to 5,000 units, and launching SmellTech-as-a-Service (SaaS) as a subscription-based revenue model.

Positive

• 412% year-over-year revenue growth in Q1 2025
• Strategic partnership with ASE Technology for deployment of up to 15,000 AI Nose units
• Smell language model achieved 90% accuracy in scent classification
• Regained Nasdaq compliance, maintaining $1.00+ share price for 10 consecutive days
• Successfully integrated AI Nose with humanoid robot platform
• Senior care program accuracy improved to 85%

Negative

• Large-scale commercialization not expected until 2026
• Initial deployment limited to 1,400 units in pilot phase

Insights

AI and Technology Investment Analyst

Ainos regains Nasdaq compliance while rapidly advancing its AI Nose technology with major partnerships and impressive 412% YoY revenue growth.

Ainos has successfully addressed a critical financial concern by regaining Nasdaq compliance, removing an immediate delisting threat that typically signals serious financial distress. This development provides essential stability for the company's future fundraising and investor confidence.

The company's AI Nose platform, powered by their proprietary smell language model (SLM), is showing promising commercial traction through three strategic partnerships: ASE Technology Holding (targeting up to 15,000 AI Nose units), Kenmec, and Solomon. These partnerships span semiconductor, industrial automation, and robotics sectors, demonstrating diverse market applications for their smell digitization technology.

Particularly noteworthy is the 412% year-over-year revenue increase in Q1 2025, primarily driven by initial AI Nose sales for senior care. This dramatic growth rate, while likely starting from a small base, validates market demand for their technology.

Their smell language model's 90% accuracy in classifying everyday scents represents a technical achievement in a nascent field. The improvement in senior care program accuracy from ~80% to ~85%, while modest, shows continued refinement.

The 90-day execution plan focuses on concrete deployments rather than just R&D, with the first phase targeting approximately 1,400 AI Nose units with ASEH, followed by expansion to 5,000 units. The company's shift toward a SmellTech-as-a-Service (SaaS) subscription model could create more predictable recurring revenue streams if successfully implemented.

While Ainos appears to be making technical progress, their current focus on partnerships in Asia suggests they're still in early market penetration phases. The projected timeline for large-scale commercialization by 2026 indicates investors should expect continued development costs before potential profitability.

Commercial Momentum Accelerates with Partnerships to Drive AI-Powered Scent Intelligence for IndustrialAI and HealthcareAI

SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 16, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization, today announced it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The compliance confirmation comes as Ainos gains momentum across its AI Nose platform, with strategic deployments, commercial partnerships, and a 90-day execution plan aimed at enabling large-scale commercialization by 2026.

"Over the past six months, we optimized our capital structure and delivered key milestones for the AI Nose platform, powered by our proprietary smell language model (SLM). We are positioning for a phase of accelerated deployment and scalable revenue generation across industrial, robotics, and healthcare sectors," said Eddy Tsai, Chairman and CEO of Ainos.

Recent AI Nose Milestones Driving Growth

• Strategic partnership with ASE Technology Holding (ASEH), the world's largest semiconductor packaging and testing company, with a targeted phased deployment plan of up to 15,000 AI Nose units.

• Expanded industrial footprint through partnerships with Kenmec and Solomon, aiming to integrate AI-powered scent intelligence powered by AI Nose and smell language model (SLM) into smart factory and machine vision ecosystems across Asia.

• Completed the world's first integration of AI Nose with a humanoid robot, for embedding digital olfactory sensing capabilities into ugo Inc.'s service robotics platform.

• Smell language model (SLM) surpassed 90% accuracy in classifying everyday scents, including meat, food, and beverages.

• Senior care program improved accuracy to ~85% from ~80%.

• 412% year-over-year revenue increase in Q1 2025, driven by initial AI Nose sales for the senior care program.

Key Strategic Priorities for the Next 90 Days

Building toward its 2026 scale-up, Ainos will focus on the following near-term priorities:

1. Complete pilot deployment of approximately 1,400 AI Nose units with ASEH and initiate Phase 1 expansion to approximately 5,000 units.

2. With Kenmec, exhibit the AI Nose integrated ugo robot at Automation Taipei, to be held August 20-23 in Taiwan.

3. Drive SmellTech-as-a-Service (SaaS) as a subscription-based revenue model for AI Nose deployments and Smell ID services.

4. Enhance SLM performance through broad-scale validation and expanded real-world testing.

5. Pursue additional strategic partnerships in Asia and Europe for technology licensing and regional commercialization.

"Regaining Nasdaq compliance is just the beginning," Tsai added. "Our mission is to build a scalable, multi-revenue platform powered by scent intelligence, transforming smell into computable, actionable business data across global markets. I believe smell will be AI's next token."

On July 15, 2025, the Company received formal notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") confirming that Ainos' common stock maintained a closing bid price of $1.00 or higher for ten consecutive business days, from June 30, 2025 to July 14, 2025. According to the Notice, the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and this matter is now officially closed.

About Ainos, Inc.

Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

Contact Information
Feifei Shen
ir@ainos.com

SOURCE: Ainos, Inc.

View the original press release on ACCESS Newswire

FAQ

What caused Ainos (AIMD) stock to regain Nasdaq compliance in July 2025?

Ainos maintained a closing bid price of $1.00 or higher for ten consecutive business days from June 30 to July 14, 2025, meeting Nasdaq's minimum bid price requirement under Rule 5550(a)(2).

How many AI Nose units will ASE Technology deploy in their partnership with Ainos?

The partnership has a phased deployment plan of up to 15,000 AI Nose units, starting with approximately 1,400 units in the pilot phase and expanding to 5,000 units in Phase 1.

What was Ainos (AIMD) revenue growth in Q1 2025?

Ainos reported a 412% year-over-year revenue increase in Q1 2025, driven by initial AI Nose sales for the senior care program.

What is the accuracy rate of Ainos' smell language model (SLM)?

Ainos' smell language model has achieved 90% accuracy in classifying everyday scents including meat, food, and beverages, while their senior care program improved to approximately 85% accuracy.

What are Ainos' key strategic priorities for the next 90 days in 2025?

Ainos will focus on completing the 1,400-unit pilot deployment with ASEH, exhibiting AI Nose integrated ugo robot at Automation Taipei, launching SmellTech-as-a-Service (SaaS), enhancing SLM performance, and pursuing additional strategic partnerships in Asia and Europe.